Aims: To elucidate the relationship between albuminuria and the prevalence of peripheral arterial disease (PAD), and to examine the effect of albuminuria on the ability to assess the likelihood of PAD in a general Japanese population.
Introduction
Peripheral arterial disease (PAD) is a manifestation of atherosclerosis. PAD in a clinical stage develops ulceration, pain, claudication, necrosis, and subsequent amputation of the lower extremities, which is one of the causes of disability among diabetic and elderly persons 1) . Recently, several studies have demonstrated that PAD is associated with higher risks of cardiovascular morbidity and mortality 2, 3) . It has been acknowledged that cardiovascular risk factors, such as aging, smoking, hypertension, diabetes, dyslipidemia, and inflammation, are linked to the presence of PAD 4) . Clinical information on these risk factors would be useful in the assessment for the risk of PAD.
The importance of kidney disease as a risk factor for atherosclerotic disease is increasingly recognized 5, 6) . Albuminuria has been shown to be linked to increased risks of cardiovascular disease, systemic atherosclerosis, and death not only in patients with diabetes or hypertension, but also in general populations 4, [7] [8] [9] . Hence, it would be of great interest to elucidate whether albuminuria substantially improves the ability to assess the likelihood for the presence of PAD beyond a model based on the known potential risk factors. Herein we present the findings of cross-sectional analyses from the Hisayama Study, which is a population-based cohort study of cardiovascular disease in Japan. The aims of this study were to investigate the relationship between albuminuria and the presence of PAD, and to evaluate the influence of albuminuria on the performance to assess the likelihood of PAD in a general Japanese population.
Methods

Study population
The Hisayama Study is a population-based prospective study of cardiovascular disease and its risk factors in the town of Hisayama, a suburb of Fukuoka City in southern Japan. The design of the study has been described in detail elsewhere 10) . The present cross-sectional study was based on a screening survey conducted in 2002. A total of 3,328 residents aged 40 years or over (77.6% of the total population of this age group) participated in the health examination and underwent a comprehensive assessment including determination of the ankle-brachial index (ABI). After the exclusion of 30 subjects who did not consent to participate in the study, 84 subjects without urine samples, and 153 subjects without information on their ankle blood pressure, the remaining 3,061 subjects (1,342 men, 1,719 women) were enrolled in the study. This study was conducted with the approval of the Kyushu University Institutional Review Board for Clinical Research. Written informed consent was obtained from all participants.
Definition of peripheral arterial disease
Blood pressure measurement for calculation of the ABI was obtained using volume-plethysmographic equipment (Form PWV/ABI; Colin, Tokyo, Japan) 11) . The ABI was calculated as ankle blood pressure divided by arm blood pressure, where the higher of the blood pressure values between the right and left arms was used. PAD was defined as ABI 0.9 in either leg 4) .
Urine albumin and creatinine ratio
A spot urine sample was obtained at the health examination visit. Urine creatinine and albumin were measured using the turbidimetric immmunoassay method. The urine albumin-creatinine ratio (UACR, in mg/g) was calculated by dividing the urinary albumin values by the urinary creatinine concentrations. UACR was categorized as normoalbuminuria (UACR 30.0 mg/g), microalbuminuria (UACR 30.0-300.0 mg/g), and macroalbuminuria (UACR 300.0 mg/g) using common cut-off points 12) . UACR levels in the normoalbuminuric range were further divided into the following tertile levels: low-normal ( 5.6 mg/g), medium-normal (5.6-10.8 mg/g), and high-normal (10.9-29.9 mg/g).
Measurement of risk factors
A self-administered questionnaire concerning the current use of antihypertensive agents, insulin, oral glucose-lowering agents, and oral medication for hyperlipidemia, smoking habits, and alcohol intake was completed in advance of the examination by each participant and was checked by trained interviewers at the screening. These variables were classified as being either habitual or not. A history of cardiovascular disease was defined as any previous events of stroke or coronary heart disease, including myocardial infarction and coronary intervention, all of which were adjudicated on the basis of clinical information including medical records and imaging.
Blood pressure was measured three times after the subject had rested for at least 5 min in the sitting position. The mean of the three measurements was used for the present analysis. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, and/or current use of antihypertensive agents. Body height and weight were measured in light clothing without shoes, and the body mass index (kg/m 2 ) was calculated. Obesity was defined as a body mass index ≥ 25.0 kg/m 2 . Serum total cholesterol concentration was determined enzymatically. Hypercholesterolemia was defined as serum total cholesterol ≥ 5.68 mmol/l (220 mg/dL) and/or current use of oral medication for hyperlipidemia. Fasting and casual blood glucose were measured by the glucose oxidase method. Diabetes mellitus was defined as fasting plasma glucose levels of ≥ 7.0 mmol/L (126 mg/dL), 2-h post-loaded or casual glucose levels of ≥ 11.1 mmol/L (200 mg/dL), and/or current use of insulin or oral glucose-lowering agents. High-sensitivity C-reactive protein (HS-CRP) was measured using a modification of the Behring LatexEnhanced CRP assay on a Behring Nephelometer BN-100 (Behring Diagnostics, Westwood, MA). High HS-CRP was defined as a serum HS-CRP level ≥ 1.0 mg/L 13) .
Statistical analysis
The trends in the mean values or frequencies of risk factors across UACR levels were tested using a linear or logistic regression model, respectively, with evenly spaced numeric codes for UACR levels. The prevalence of PAD was adjusted for the age and sex distribution of the overall study population enrolled in this study using a direct method. The statistical differences in prevalence and their trends among UACR levels were estimated using the logistic regression model, where age and sex were included. The age-and sex-adjusted or multivariate-adjusted odds ratio (OR) and its 95% confidence interval (CI) for the presence of PAD were assessed by fitting the logistic regression model with adjustment for potential confounding covariates. The confounding covariates included in the relevant model, such as hypertension, diabetes mellitus, hypercholesterolemia, obesity, high HS-CRP, history of cardiovascular disease, smoking habits, and alcohol intake, were used as binary categorical variables. The heterogeneity in the relationship between subgroups was tested by adding a multiplicative interaction term to the relevant statistical model. To compare the accuracy of the ability to assess the likelihood of PAD between the models adjusted for potential risk factors with and without UACR levels, the receiver operating characteristic (ROC) curves were plotted.
The consistency of the area under the ROC curve among models was estimated using DeLong's method 14) . All the statistical analyses were performed using the SAS software package, release 9.2 (SAS Institute, Cary, USA). A two-tailed value of p 0.05 was considered statistically significant.
Results
The prevalence of microalbuminuria and macroalbuminuria was 17.0% and 2.4%, respectively, in this population. The clinical characteristics of the study population are summarized in Table 1 according to UACR levels. The mean values of age, systolic and diastolic blood pressures, and the frequencies of the following parameters increased significantly with elevated UACR levels: use of antihypertensive drugs, hypertension, diabetes, hypercholesterolemia, obesity, high HS-CRP, and a history of cardiovascular disease. Decreasing trends in the frequencies of men, smoking habits, and alcohol intake were found in higher UACR levels.
Overall, 45 (1.47%) of the study participants had PAD. The age-and sex-adjusted prevalence of PAD increased linearly for higher UACR levels of 5.6, 5.6-10.8, 10.9-29.9, 30.0-300.0, and 300.0 mg/g, being 0.34, 0.80, 2.02, 2.50, and 2.53%, respectively ( p for trend 0.001) (Fig. 1) . After adjusting for potential confounding factors, namely, age, sex, hypertension, diabetes, hypercholesterolemia, obesity, high HS-CRP, history of cardiovascular dis- ease, smoking habits, and alcohol intake, the OR for the presence of PAD increased progressively as UACR levels became elevated ( Table 2 ). The multivariate-adjusted OR for the presence of PAD was 1.85 (95% CI, 1.12-3.06) for every 10-fold increment in UACR. The sensitivity analyses, excluding subjects with macroalbuminuria (n 73) or subjects having a much higher ABI of ≥ 1.4 (n 2), did not make any material differences in the findings of this study (data not shown).
We also performed subgroup analyses to estimate the effect of cardiovascular risk factors on the relationship between PAD and UACR ( Table 3) . Overall, there was no evidence for statistically significant differences in the magnitudes of the multivariate-adjusted ORs across UACR levels for the risk of prevalent PAD among subgroups of cardiovascular risk factors (all p for interaction 0.09); however, the association between UACR and PAD tended to be stronger in current smokers than in non-smokers ( p for interaction 0.097).
Finally, we assessed the effect of UACR on the assessment for the likelihood of prevalent PAD by comparing the areas under the ROC curves between the models with and without UACR (Fig. 2) . The area under the ROC curve significantly increased when UACR levels were incorporated into a model with potential risk factors for PAD (0.80 vs. 0.77, p 0.02). The same was true after excluding subjects with a history of cardiovascular disease (0.79 vs. 0.74, p 0.03).
We also performed sensitivity analyses including systolic blood pressure taken as a continuous variable and use of antihypertensive medication in the relevant model, instead of the binary variable of hypertension. As a result, the finding was not altered substantially: the multivariate-adjusted OR for the presence of PAD for every 10-fold increment in UACR was 1.71 (95% CI, 1.02-2.89), and the area under the ROC curve for the model assessing the likelihood of PAD increased when UACR was added to the model (0.80 vs. 0.78, p 0.05).
Discussion
In the present study, we clearly demonstrated that albuminuria was associated linearly with an increasing likelihood for the presence of PAD, even in the normoalbuminuric range. This association remained unchanged even after controlling for the potential confounding factors, namely, age, sex, hypertension, diabetes, hypercholesterolemia, high HS-CRP, history of cardiovascular disease, smoking habits, and alcohol intake. Importantly, our findings re- vealed that the incorporation of albuminuria to a model with potential risk factors significantly improved the assessment of the likelihood for the presence of PAD in a general population. To the best of our knowledge, this is the first study statistically elucidating the clinical value of albuminuria in the likelihood assessment for PAD. These findings therefore highlight the potential additive value of the measurement of albuminuria in the risk assessment for PAD for the general population, especially for individuals with smoking habits. There has been conflicting evidence in the literature regarding the association between albuminuria and the presence of PAD, especially according to the diabetic status 8, 9, 15) . The Islington Diabetes Survey first suggested that the prevalence of PAD defined as ABI 0.9 was higher in subjects with albuminuria among non-diabetic subjects 16) . The Strong Heart Study, in which about half of the study population had diabetes, showed that the magnitude of the effect PAD, peripheral arterial disease; OR, odds ratio; UACR, urinary albumin-creatinine ratio; CI, confidence interval; HS-CRP, high-sensitivity C-reactive protein a) Adjusted for age, sex, hypertension, diabetes mellitus, hypercholesterolemia, obesity, high HS-CRP, history of cardiovascular disease, smoking habits, and alcohol intake. The variable relevant to the subgroup was excluded from each model. of albuminuria on the risk for the presence of PAD was comparable to that of other cardiovascular risk factors, such as hypertension, diabetes, and smoking in Native Americans 4) . Some cross-sectional studies in large community-derived populations found that diabetic subjects with albuminuria had approximately twice the risk for the presence of PAD than those without albuminuria, but this relationship was absent in non-diabetic subjects 8, 15) . By contrast, the recent results from the National Health and Nutrition Examination Surveys (NHANES) 1999-2004 revealed that the association of albuminuria with the risk of prevalent PAD applied to non-diabetic subjects but not to diabetic subjects 9) . The present study indicated that higher UACR levels were associated with an increased risk of the presence of PAD, without any clear evidence of heterogeneity in the association between subgroups of subjects with diabetes in a general Japanese population. These diverse findings may arise from insufficient statistical power to perform a reliable subgroup analysis due to the small number of PAD cases in these studies, including ours. Further large-scale community-based studies or meta-analyses are needed to clarify this issue.
Most notably, the present study clearly demonstrated that adding albuminuria to a model involving potential risk factors significantly improved the assessment of the likelihood of the presence of PAD. A recent statement about the clinical scientific research 17) recommends that studies of a novel risk marker should report whether the incorporation of the new marker improves the risk assessment performance provided by established risk markers, but there have been limited studies assessing the improvement by the new marker so far. Additionally, the risk assessment for PAD may be more clinically useful in people without a history of cardiovascular disease rather than those with it, because people with prior cardiovascular disease are obviously considered as a high-risk population of any other vascular diseases. Importantly, our sensitivity analysis revealed that the incorporation of UACR levels into the model significantly improved the risk assessment ability for PAD even in people without a history of cardiovascular disease. Therefore, we believe that our findings provide strong evidence that albuminuria should be evaluated as an important factor in the risk assessment of PAD.
The mechanism through which the relationship between albuminuria and PAD may be mediated is an area of great interest. Albuminuria is suggested to be a manifestation of systemic endothelial dysfunction, which reflects the severity of vascular disease 18) . It has been acknowledged that subjects with greater albuminuria also show a higher prevalence of traditional cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, and smoking habits 15, 19) . Additionally, chronic inflammation has been shown to be involved in the relationship between albuminuria and PAD 20) . The burden of these risk factors is likely to cause endothelial dysfunctions and subsequent vascular damage. Furthermore, the fact that the significant relationship between albuminuria and PAD was still observed after adjusting for these risk factors in the present study may suggest the existence of residual confounders such as the involvement of oxidative stress or asymmetric dimethylarginine 21) and the duration of the underlying disease. Further studies are warranted to better elucidate the mechanism underlying the relationship between albuminuria and PAD.
In the present study, the effect of albuminuria on the likelihood of prevalent PAD tended to be greater in current smokers than in non-smokers, although the Model 1 included age, sex, hypertension, diabetes mellitus, hypercholesterolemia, obesity, high high-sensitivity C-reactive protein, history of cardiovascular disease, smoking habits, and alcohol intake. Abbreviations: UACR, urinary albumin-creatinine ratio; CI, confidence interval statistical power of this tendency was insufficient to show a significant difference in the effects. The results from the NHANES and a case-control study conducted in 82 hypertensive patients revealed that heavy current smokers were likely to have a greater amount of albuminuria among hypertensive subjects 22, 23) . Smoking has numerous effects, such as oxidative stress, systemic inflammation, hemostatic and coagulation activation 24, 25) , and deteriorating vascular disease in parallel with the induction of albuminuria. Our findings imply the importance of paying particular attention to subjects with smoking habits and albuminuria as a population at higher risk of PAD.
Several limitations should be noted. First, the cross-sectional study design limits the interpretation of causality between albuminuria and PAD. Second, albuminuria levels were determined by a single measurement, which may not be accurately representative of the status of the study participants. This weakens the association found in this study, biasing the results toward the null hypothesis. Third, the diagnosis of PAD was determined on the basis of ABI, but not angiography; however, it has been well acknowledged that ABI is a noninvasive and reproducible procedure for detecting preclinical PAD, and it is suitable for mass screening. Fourth, our study was unable to identify the relationship between albuminuria and extremely high ABI, which is also considered to signify advanced arteriosclerosis, because very few subjects (n 2) had an ABI of ≥ 1.4 in this study; however, sensitivity analysis excluding subjects with ABI of ≥ 1.4 did not alter the findings substantially.
Conclusion
In conclusion, greater UACR levels, even in the normoalbuminuric range, are associated linearly with a higher prevalence of PAD in the general Japanese population. Routine measurement of albuminuria therefore improves the current tools available for the likelihood assessment of PAD. Our findings suggest that the clinical assessment of and early intervention for PAD should be considered in people with albuminuria.
